|Bid||2.8200 x 1300|
|Ask||2.8300 x 1000|
|Day's Range||2.7900 - 2.9800|
|52 Week Range||0.7800 - 5.9800|
|Beta (5Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2021 financial results and provided a corporate update.
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.